Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The …
…, S Corallo, C Manai, F Tosi, P Manca, F Daniel, V Torri… - 2021 - ascopubs.org
3506 Background: Despite advances in molecular segmentation of metastatic colorectal
cancer (mCRC), beyond RAS status therapeutic actionability remains confined to the limited …
cancer (mCRC), beyond RAS status therapeutic actionability remains confined to the limited …
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial.
…, K Bencardino, F Leone, V Zagonel, E Valtorta, V Torri… - 2015 - ascopubs.org
3508 Background: We conducted a phase II of trastuzumab (T) and lapatinib (L) in HER2-amplified,
KRAS exon 2 wild-type, mCRC pts resistant to standard therapies (HERACLES Trial …
KRAS exon 2 wild-type, mCRC pts resistant to standard therapies (HERACLES Trial …
Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer
Cyclic FMD is well tolerated and causes remarkable systemic metabolic changes in patients
with different tumor types and treated with concomitant antitumor therapies. In addition, the …
with different tumor types and treated with concomitant antitumor therapies. In addition, the …
[HTML][HTML] Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
…, RJ Stephens, A Dunant, V Torri… - Database of Abstracts …, 2008 - ncbi.nlm.nih.gov
This meta-analysis of individual patient data concluded that postoperative cisplatin-based
chemotherapy significantly improved survival compared with no chemotherapy in patients with …
chemotherapy significantly improved survival compared with no chemotherapy in patients with …
Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints
MKB Parmar, V Torri, L Stewart - Statistics in medicine, 1998 - Wiley Online Library
Meta‐analyses aim to provide a full and comprehensive summary of related studies which
have addressed a similar question. When the studies involve time to event (survival‐type) …
have addressed a similar question. When the studies involve time to event (survival‐type) …
Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial
…, D Giannarelli, R Fossati, V Torri… - JNCI: Journal of the …, 2008 - academic.oup.com
Background Pelvic lymph nodes are the most common site of extrauterine tumor spread in
early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been …
early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been …
[HTML][HTML] Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
…, AJ French, B Kabat, NR Foster, V Torri… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Prior reports have indicated that patients with colon cancer who demonstrate high-level
microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have …
microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have …
Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).
…, F Grossi, M Mencoboni, A Bearz, I Floriani, V Torri… - 2013 - ascopubs.org
LBA8005 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT)
on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement …
on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement …
[HTML][HTML] COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
…, JG Whisenant, LC Huang, A Trama, V Torri… - The Lancet …, 2020 - thelancet.com
Background Early reports on patients with cancer and COVID-19 have suggested a high
mortality rate compared with the general population. Patients with thoracic malignancies are …
mortality rate compared with the general population. Patients with thoracic malignancies are …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
…, P Racca, A Bertotti, G Siravegna, V Torri… - The Lancet …, 2016 - thelancet.com
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …